SV HEALTH MANAGERS LLP

1. SV HEALTH MANAGERS LLP 2017-07-21 → present
2. SV LIFE SCIENCES MANAGERS LLP 2004-08-02 → 2017-07-21

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The members have prepared forecasts covering a period of 12 months following the signing of these financial statements and, after making enquiries, have a reasonable expectation that the operating cashflows of the LLP will continue to be positive, due to the fee income generated from investor commitments to the partnerships managed by the LLP.”

Group structure

1. SV HEALTH MANAGERS LLP · parent
   1. SV DDF Number 1 Ltd · England and Wales
   2. SV DDF Number 2 Ltd · Scotland
   3. Dementia Discovery GP LLP (DD GP LLP) · England and Wales
   4. Dementia Discovery GP LP (DD GP LP) · Scotland
   5. SV7 (IMF) FP GP LLP · England and Wales
   6. SV7 (IMF) FP LP · Scotland
   7. SV7 (IMF) GP LLP · England and Wales
   8. SV BCO I FP GP LLP · England and Wales
   9. SV BCO I FP LP · Scotland
   10. SV BCO I GP LLP · England and Wales
   11. DDF 2 FP GP LLP · England and Wales
   12. DDF 2 FP LP · Scotland
   13. DDF 2 GP LLP · England and Wales
   14. SV8 Bio FP GP LLP · England and Wales
   15. SV8 Biotech FP LP · Scotland
   16. SV8 Bio GP LLP · England and Wales

Significant events

• “The Partnership continued its fundraising activities in 2025. Dementia Discovery Fund 2 ("DDF 2") held its final close on 16 May 2025, securing additional commitments and increasing total funds under management.”
• “Dementia Discovery LP continued to make follow-on investments across its portfolio, and its final listed holding, Alector, was fully exited during the year.”
• “SV7 Impact Medicine Fund ("SV7 IMF") reached the end of its investment period in the first half of the year and completed several follow-on investments.”
• “SVHM's latest flagship fund, SV8 Biotech Fund LP ("SV8"), held its first close in December 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +19.1%

  £15,308,000 → £18,226,000

• Cash

  +48.8%

  £2,085,000 → £3,102,000

• Net assets

  +9.4%

  £3,664,000 → £4,008,000

• Employees

  0%

  17 → 17

• Operating profit

  +10%

  £4,722,000 → £5,193,000

• Wages

  +19%

  £2,569,000 → £3,056,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers